Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial by Linda Mileshkin, Elizabeth Barnes, Tarek Meniawy, Kristy Robledo, Michael Friedlander, Geraldine Goss, Jermaine Coward, Yoland Antill, Michelle Cummins, Sally Baron-Hay, Martin R Stockler, Catherine Shannon, Philip Beale, Peey-Sei Kok, Deborah Smith, Sonia Yip, Amanda Spurdle, Yeh Chen Lee, Janine Lombard, John Andrews

Get full text